Bayer's Legal and Financial Horizon Hinges on a Fortnight of Decisions

Bayer faces a pivotal Supreme Court hearing on glyphosate litigation and a major settlement, as it reaffirms financial targets and sees strong growth from its kidney drug Kerendia.

The coming weeks present a critical convergence of events for Bayer, with a shareholder meeting and a landmark Supreme Court hearing poised to shape the German conglomerate's immediate trajectory. At the heart of the matter lies the persistent legal shadow of glyphosate litigation, a multi-billion dollar burden that has weighed on the stock for years. A favorable ruling from the highest U.S. court could fundamentally alter that landscape.

Oral arguments in the pivotal case Durnell v. Monsanto are scheduled for April 27 before the U.S. Supreme Court. Bayer's core argument rests on federal preemption, contending that the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA) supersedes state warning-label laws, as the U.S. Environmental Protection Agency has not mandated a cancer warning on Roundup labels. The court's decision, expected by June, carries extraordinary stakes. Since acquiring Monsanto in 2018, Bayer has paid over $11 billion in settlements and verdicts, with more than 100,000 claims still pending. A ruling in Bayer's favor could drastically reduce provisions for future litigation and trigger a sustained re-rating of the stock.

The legal path has been contradictory. While two appellate courts have rejected Bayer's preemption argument, a third—the Third Circuit Court of Appeals—ruled in the company's favor. This split in legal interpretation is precisely why the Supreme Court agreed to hear the case. Opposition is notable, with attorneys general from Texas, Florida, and Ohio filing amicus briefs against Bayer's position; a total of 18 such briefs have been submitted.

Parallel to this, a massive settlement is progressing. In February 2026, a $7.25 billion settlement was announced in the case King v. Monsanto, aimed at resolving current and future non-Hodgkin lymphoma claims. Judge Timothy J. Boyer granted preliminary approval to this settlement in March.

Amid this legal tension, Bayer's management has reaffirmed its financial guidance. The company is targeting currency-adjusted sales of 45 to 47 billion euros for 2026, alongside an EBITDA before special items of 9.6 to 10.1 billion euros. Pharmaceuticals COO Sebastian Guth addressed recent market concerns, clarifying that potential U.S. import tariffs on medicines are capped at 15 percent under an existing EU-U.S. trade agreement and are already factored into budget planning for 2026.

Operationally, the kidney drug Kerendia is emerging as a powerful growth engine within the pharmaceuticals division. It posted a currency-adjusted sales increase of 88 percent in 2025. A recent EU label expansion for treating heart failure opens access to several million additional patients in Europe, with management targeting peak sales exceeding three billion euros long-term. To bolster its U.S. presence, Nelson Ambrogio will assume leadership of Bayer U.S. Pharmaceuticals on May 1, tasked with maintaining growth momentum despite patent expiries for older blockbusters.

The financial picture, however, remains strained. Despite stable operational performance, management anticipates a negative free cash flow for 2026 due to payouts from ongoing legal disputes. Net financial debt stood at approximately 29.8 billion euros at the end of 2025, which is still 8.5 percent lower than the previous year.

Ahead of the Supreme Court hearing, shareholders will gather for the Annual General Meeting on April 24. The agenda includes a vote on a dividend of 0.11 euros per share and the election of two new supervisory board members. The meeting's focus, however, will undoubtedly be drawn toward the legal proceedings just days later.

Analyst sentiment has recently shifted, reflecting the potential for a legal turning point. DZ Bank executed a notable reversal over the weekend, upgrading its rating from "Sell" to "Hold" and raising its fair value estimate to 44 euros. The bank cited improved calculability of glyphosat litigation risks as the reason. Meanwhile, UBS analyst Matthew Weston reiterated his "Buy" recommendation and 52-euro price target, implying an upside of roughly 30 percent from current levels around 40 euros. The bank expects no negative surprises from the quarterly report due in May.

For Bayer, the path to a sustained recovery appears to hinge on a favorable Supreme Court decision. Management has pointed to 2027 as a potential inflection point for financial recovery. Whether that outlook holds will be significantly determined by the judges in Washington, making the final week of April a defining period for the company's future.